Anti‐PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care

OBJECTIVES: To put data from our recent systematic review of phase 3 studies of anti‐proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies into the context of clinical practice. METHODS: Data from studies previously identified by a systematic review of phase 3 studies of alirocumab and ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Descamps, Olivier S., Fraass, Uwe, Dent, Ricardo, März, Winfried, Gouni‐Berthold, Ioanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Cardiovascular Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601297/
https://www.ncbi.nlm.nih.gov/pubmed/28750477
http://dx.doi.org/10.1111/ijcp.12979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601297/
https://www.ncbi.nlm.nih.gov/pubmed/28750477
http://dx.doi.org/10.1111/ijcp.12979

Ejemplares similares